Coya Therapeutics, Inc. (COYA) Thursday reported positive interim results from an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD).
In the study, patients received CTLA4-Ig, followed by a low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. Data from the first 5 patients with mild to moderate FTD showed a rapid and durable statistically significant increase in the number and suppressive function of regulatory T cells (Tregs), that play a crucial role in regulating the immune system, compared to baseline values.
Patients with FTD demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, and no serious adverse events were reported.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.